![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sofosbuvir in Combination With PegIFN and
Ribavirin for 12 Weeks Provides High SVR Rates
in HCV-Infected Genotype 2 or 3 Treatment-
Experienced Patients with and without
Compensated Cirrhosis: Results from the LONESTAR-2 Study
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-4, Washington, DC
Eric Lawitz1,2, Fred Poordad1,2, Diana M. Brainard3, Robert H. Hyland3, Di An3,
William T. Symonds3, John G. McHutchison3, Fernando E. Membreno1,2
1Texas Liver Institute, San Antonio, TX; 2University of Texas Health Science Center, San Antonio, TX; 3Gilead Sciences, Inc, Foster City, CA
![AASLD1.gif](../images/110313/110313-7/AASLD1.gif)
![AASLD2.gif](../images/110313/110313-7/AASLD2.gif)
![AASLD3.gif](../images/110313/110313-7/AASLD3.gif)
![AASLD4.gif](../images/110313/110313-7/AASLD4.gif)
![AASLD5.gif](../images/110313/110313-7/AASLD5.gif)
![AASLD6.gif](../images/110313/110313-7/AASLD6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|